EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program SALT LAKE CITY, Utah - July 23, 2026 - SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced biomaterials and silicon nitride technologies for medical device and industrial applications, today announced that it has engaged Southern Metrics Consulting (“Southern Metrics”) to assist the Company in identifying, evaluating, and pursuing strategic opportunities intended to enhance stockholder value. Southern Metrics is led by Chris Lyons, its Chief Executive Officer, an experienced medical technology executive and strategic advisor who has served on the SINTX Board of Directors since April 2025. Southern Metrics will establish and manage the Company’s newly created Strategic Opportunity Management Program. The Strategic Opportunity Management Program is designed to provide a disciplined, proactive framework for identifying, evaluating, prioritizing, and managing strategic opportunities that support SINTX’s long-term growth strategy and enhance stockholder value. Wor…
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
SiNtx Technologies, Inc.
SINTNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 9.01 Financial Statements and Exhibits. Exhibit Description No. ────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release, dated July 23, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Company context
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities, and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SINAPTIC Foot & Ankle Implant System for reconstructive surgery.